Letrozol Amperlem

Letrozole, the active ingredient in Letrozol Amperlem, is an aromatase inhibitor presented as an oral tablet for oral use. It is used to treat postmenopausal hormone receptor‑positive breast cancer and as adjuvant therapy for early‑stage disease. GNH USA supplies Letrozol Amperlem as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozol Amperlem is an aromatase inhibitor used in hormone‑driven breast cancer management.

Postmenopausal hormone receptor‑positive breast cancer: reduces estrogen‑driven tumor growth and lowers recurrence risk. Adjuvant therapy for early‑stage breast cancer: decreases estrogen levels to prevent disease progression. Estrogen‑dependent breast cancer: limits peripheral conversion of androgens to estrogen, inhibiting tumor proliferation.

Letrozol Amperlem may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching or stiffness in limbs. - Fatigue: persistent tiredness not relieved by rest. - Nausea or mild gastrointestinal upset. - Headache: intermittent or persistent head pain. - Increased sweating.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes, hepatic failure. - Bone fractures: decreased bone mineral density leading to fractures. - Pulmonary embolism: sudden shortness of breath, chest pain. - Severe allergic reaction: rash, swelling, anaphylaxis. - Elevated cholesterol levels: risk of cardiovascular events. - QT interval prolongation: potential cardiac arrhythmias.

Before initiating Letrozol Amperlem, clinicians should consider several safety measures.

Monitor bone health: assess bone mineral density regularly. Evaluate liver function: perform baseline and periodic liver enzyme tests. Assess cardiovascular risk: review history of thrombosis or hyperlipidaemia. Avoid use in premenopausal women: drug is ineffective and may cause ovarian stimulation. Review concomitant medications: check for interactions that may alter letrozole levels. Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Letrozol Amperlem can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Estrogen‑containing products: may counteract letrozole’s estrogen‑lowering effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can markedly reduce letrozole exposure. - Warfarin: may increase anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): may raise letrozole plasma levels. - Selective serotonin reuptake inhibitors (SSRIs): potential modest increase in side‑effects. - Statins: monitor for additive liver enzyme elevations. - Glucocorticoids: observe for enhanced bone density loss.